Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
FEBS Letters|June 26, 2026
Mixed-class J-domain protein scaffolds promote expanded aggregate handling and multivalent Hsp70 engagement during functional disaggregase assemblyAnna Szlachcic, Nadinath B Nillegoda
Biotechnology Advances|March 30, 2011
Longer action means better drug: tuning up protein therapeuticsAnna Szlachcic, Malgorzata Zakrzewska, Jacek Otlewski
Current Pharmaceutical Biotechnology|September 10, 2011
Tailoring small proteins towards biomedical applicationsMalgorzata Zakrzewska, Anna Szlachcic, Jacek Otlewski
Drug Design, Development and Therapy|August 27, 2016
Design and characteristics of cytotoxic fibroblast growth factor 1 conjugate for fibroblast growth factor receptor-targeted cancer therapyAnna Szlachcic, Malgorzata Zakrzewska, Michal Lobocki, et al.
FEBS Open Bio|April 11, 2019
Identification of a peptide antagonist of the FGF1-FGFR1 signaling axis by phage display selectionMagdalena Lipok, Anna Szlachcic, Kinga Kindela, et al.
International Journal of Molecular Sciences|July 22, 2018
FGF2 Dual Warhead Conjugate with Monomethyl Auristatin E and α-Amanitin Displays a Cytotoxic Effect towards Cancer Cells Overproducing FGF Receptor 1Karolina Weronika Świderska, Anna Szlachcic, Łukasz Opaliński, et al.
The Journal of Biological Chemistry|July 4, 2009
Increased protein stability of FGF1 can compensate for its reduced affinity for heparinMalgorzata Zakrzewska, Antoni Wiedlocha, Anna Szlachcic, et al.
International Journal of Nanomedicine|December 11, 2012
FGF1-gold nanoparticle conjugates targeting FGFR efficiently decrease cell viability upon NIR irradiationAnna Szlachcic, Katarzyna Pala, Malgorzata Zakrzewska, et al.
Acta Crystallographica. Section C, Crystal Structure Communications|March 6, 2010
Two pentadehydropeptides with different configurations of the DeltaPhe residuesMaciej Makowski, Marek Lisowski, Anna Maciag, et al.
Frontiers in Pharmacology|December 6, 2021
Peptibody Based on FGFR1-Binding Peptides From the FGF4 Sequence as a Cancer-Targeting AgentKarolina Jendryczko, Jakub Rzeszotko, Mateusz Adam Krzyscik, et al.
Pageof 3